secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059329
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics reports Q1 net loss $26M; GSBR-1290 Phase 2a obesity data due June 2024
--------------------------------------------------------------------------------

- Net loss $26.0M in Q1 2024 vs $18.0M in Q1 2023; cash $436.4M funds projected operations through at least 2026.
- Topline GSBR-1290 Phase 2a obesity 12-week data for 40 participants expected June 2024; Phase 2b obesity study to start Q4 2024.
- R&D expenses $20.7M (+58% YoY) driven by GLP-1R franchise; G&A expenses $11.3M (+74% YoY) from public company infrastructure.
- Plan to initiate first-in-human Phase 1 trial of LTSE-2578 (oral LPA1R antagonist for IPF) in June 2024.
- Amylin candidate selection expected Q4 2024; GIPR candidate selection H1 2025; ANPA-0073 (APJR) Phase 1 completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465924059329/0001104659-24-059329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465924059329/tm2413721d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer